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Abstract
Objectives The aim of the study was to determine the extent
of inter-individual variation in clearance of intravenous mor-
phine in children and to establish which factors are responsi-
ble for this variation.
Methods A systematic literature review was performed to
identify papers describing the clearance of morphine in chil-
dren. The following databases were searched: Medline,
Embase, International Pharmaceutical Abstracts, CINAHL,
and Cochrane library. From the papers, the range in plasma
clearance and the coefficient of variation (CV) in plasma
clearance were determined.
Results Twenty-eight studies were identified. After qual-
ity assessment, 20 studies were included. Only 10 stud-
ies gave clearance values for individual patients. The
majority of the studies were in critically ill patients.
Inter-individual variability of morphine clearance was
observed in all age groups, but greatest in critically ill
neonates (both preterm and term) and infants. In criti-
cally ill patients, the CV was 16–97 % in preterm ne-
onates, 24–87 % in term neonates, 35 and 134 % in
infants, 39 and 55 % in children, and 74 % in adoles-
cents. The CV was 37 and 44 % respectively in non-
critically ill neonates and infants. The mean clearance
was higher in children (32 and 52 ml min-1 kg-1) than
in neonates (2 to 16 ml min-1 kg-1).
Conclusions Large inter-individual variation was seen inmor-
phine clearance values in critically ill neonates and infants.
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Introduction
Morphine is a naturally occurring opioid alkaloid. It is the first
choice analgesic for severe pain and can be used for preoper-
ative sedation. Morphine can be administered via different
routes intravenously (IV), intramuscularly (IM), subcutane-
ously (SC), orally, and rectally. There are two major formula-
tions of oral morphine: immediate release, which has exten-
sive inter-individual variation for bioavailability and con-
trolled release morphine, which is less variable. Bioavailabil-
ity is approximately 30–40 % [1].
Dosing varies according to the age, route of administration,
and is based on body weight [2–4]. Due to patients’ varied
response to pain, morphine dose is usually titrated according
to clinical response. Paediatric dosing for drugs is sometimes
determined from adult pharmacokinetic studies. However, re-
sults from adults are difficult to extrapolate to children, be-
cause the physiological makeup of the two age groups is dif-
ferent. Pharmacokinetic studies in children therefore help to
ensure that the appropriate drug dose is administered. Doses
are usually calculated from mean pharmacokinetic values.
There is however often significant variability in pharmacoki-
netics due to factors such as age [5], weight [6], disease [7],
and ethnicity/genotype [8]. Recent advances in research has
resulted in the development of PK–models to ensure the ap-
propriate individualisation of dosing in children [9].
We have previously evaluated inter-individual varia-
tion in the clearance of midazolam [10]. We wished to
explore inter-individual variation in morphine clearance
in paediatric patients and we therefore performed a sys-
tematic review of pharmacokinetic studies in paediatric
patients involving morphine. The metabolite morphine-
6-glucuronide (M6G) is more potent as an analgesic
than morphine itself. We therefore also looked at M6G
to morphine ratios.
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Methods
A systematic literature search was performed to identify all
papers describing the clearance of morphine in children. The
following databases were utilised; MEDLINE (1946 to May
2013), EMBASE (1974 to May 2013), International Pharma-
ceutical Abstracts (1970 to April 2013), CINAHL, and
Cochrane Library. The databases were searched separately
and combined together to remove duplications. The search
strategy included all languages and involved the keywords
Bmorphine AND Bchild*^ OR Bp*ediatric* OR Binfant*^
OR Bnew-born*^ OR Bneonate*^ OR Badolescent*^ [11]
AND Bpharmacokinetic*^ OR Bclearance^ OR Bhalf-life^
OR Babsorption^ OR Bdistribution^ OR Bmetabolism^ OR
Belimination^ OR *^.
Inclusion criteria were original research studies assessing
the pharmacokinetics of morphine in children up to the age of
18 years. We excluded the following: review articles, edito-
rials, conference abstracts, studies in adults aged 18 years and
over, and studies that involved adults and paediatric patients
where the paediatric data was not presented separately. Studies
in which morphine was not administered intravenously were
also excluded.
Data such as, number of patients, ethnicity, dose, and
clearance were extracted. The mean/median clearance,
as well as both the minimum and maximum clearance
values were noted. The variation ratio was calculated
from the range of clearance (maximum clearance divid-
ed by the minimum clearance).The coefficient of varia-
tion (CV) was extracted from the paper if given. If
individual data was presented, then the CV was calcu-








which allows for the fact that clearance is usually log nor-
mally distributed in children. If individual data was not avail-
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Fig. 1 Flow chart of the search
performed
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deviation by the mean of clearance, i.e., normal distribution
assumed. The variation ratio for M6G/M was calculated by
dividing the maximum M6G/M by the minimum M6G/M.
Patients were divided into two groups: (1) critically ill if they
were in an intensive care unit and (2) non-critically ill which
included other groups. We also contacted original authors by
email if their paper did not give the full range of clearance
values but gave mean clearance values.
Results
A total of 2040 articles were identified, but only 28 articles
(studies) met the inclusion criteria [5, 7, 13–38] (Fig. 1).
Eight studies were excluded after quality assessment
(Supplementary table 3) [19, 23, 29–31, 35–37]. For one
study, some of the data were excluded [5]. A total of 20 studies
were included after quality assessment.
The majority of the studies (19) used non-compartmental
methods. Only one used a two-compartmental model [34].
Ethnicity was not described in any study. The CV was not
stated in any study. Ten studies provided individual data
allowing calculation of CV [5, 7, 13–16, 18, 24, 28, 32]. In
six studies, only the standard deviation (SD) was reported, and
therefore, CV was estimated, assuming normal distribution
[17, 20–22, 26, 34]. Three studies did not report either SD
or CVof morphine clearance [25, 27, 33].
All the studies, except two, involved critically ill patients
[5, 27]. Thirteen studies reported morphine clearance in 228
critically ill neonates (Table 1) [5, 13–18, 20–22, 24–26].
Details of the administration of morphine and the number
of blood samples collected to calculate clearance are given in
Supplementary Table 1.
Nine of the neonatal studies were in preterm neonates (n=
166) with CV ranging from 16 to 97 %. The CV for term
neonates (n=62) varied between 24 and 87 %. There was 2–
14-fold inter-individual variation of clearance in preterm neo-
nates and 3–20-fold variation in term neonates. The range in
clearance is shown in Fig. 2.
There were four studies involving 53 infants (Table 2) [24,
25, 27, 28].
Two of these studies involved both critically ill and non-
critically ill patients (Table 3).
One of these studies involved both term neonates and
infants with CV of 37 and 44 %, respectively [5]. The
other study involving infants did not report the CV.
However, variation ratios in these studies were twofold
and threefold [5, 27]. The CV of morphine clearance in
critically ill infants was 35 and 134 %. The variation
ratio in studies involving critically ill infants was be-
tween 2- and 11-fold.
Two studies reported clearance in 12 critically ill children
[28, 32]. The CV in these studies was 39 and 55 %. These
studies gave the full range of clearance for inter-individual
children. The variation ratio of clearance was threefold for
both studies. Only one study involved adolescents. The four
critically ill adolescents had CVof 74 % and variation ratio of
threefold [32].
Three studies involved a combination of more than one age
group [7, 33, 34]. The highest CV of 39 % was in a study
involving patients aged 6–19 years, whilst the lowest CV of
25 % was in patients aged 7 months–7 years. The degree of
variability in clearance was between 2- and 10-fold. The co-
efficients of variation in different age groups are summarised
in Table 4.
Three studies reported the ratio of M6G to morphine
(Supplementary table 2) [18, 33, 38]. The variation ratio in
neonates ranged between 4- and 33-fold. One study in infants
reported variation ratio of 12-fold.
Discussion
Inter-individual variation was greatest in critically ill neonates
and infants. Inter-individual variation was lowest in non-
critically ill patients. The variation ratio in clearance in criti-
cally ill neonates ranged from 2- to 20-fold with the coefficient
of variation going up to 96 %. In infants, the variation ratio
ranged from 2- to 11-fold with the coefficient of variation up
to 134 %. In contrast, the variation ratio in non-critically ill
patients and critically ill children and adolescents was less
than fourfold (with the exception of one study in critically ill
children where it was almost 10-fold).
Intravenous morphine is administered as a fixed dose bolus
(50 μg/kg in neonates and 100 μg/kg in infants and children
up to the age of 12 years [4]. It is then given as an intravenous
infusion with a fourfold variation in dosage in neonates (5–
20 μg/kg/h) and lower variation in infusion rates in infants
(10–30 μg/kg/h) and children (20–30 μg/kg/h). The dose is
then titrated according to clinical response. Titration of dose is
essential due to the large inter-individual variation in clear-
















































Fig. 2 Mean and range of clearance for different patient age groups (for
studies with individual data of CL)
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in neonates suggests that the variation in dosage requirements
in order to achieve adequate pain relief is far greater than that
currently recommended.
The large inter-individual variation in critically ill neonates
and infants is similar to our previous study on inter-individual
variation in midazolam clearance in children. In contrast, there
was, however, less inter-individual variation in critically ill
children and adolescents with morphine than with midazolam.
Critically ill patients tend to have impaired renal and
hepatic function. Hepatic blood flow and hepatocellular
function are altered, and consequently, hepatic clearance
of morphine can be impaired [39]. Critically ill children
are also at risk of acute renal failure. Impairment of
morphine clearance prolongs the drug half-life and ac-
cumulation of drugs may occur, leading to toxicity [40].
Conditions such as sepsis, major surgery, and use of
nephrotoxic drugs can damage the kidneys thereby al-
tering the pharmacokinetic parameters of morphine [41].
In conclusion, large inter-individual variation was seen in
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